Oppenheimer & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
Other funds holding BMRN
Oppenheimer & Co's BMRN Position: Q3 2026 in Review
Oppenheimer & Co held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2026 at 4,656 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #1465.
Oppenheimer & Co first reported a position in BMRN in Q4 2013 and has held it in 14 quarters since. The position peaked at $1.62M in Q2 2015. 567 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.
- Oppenheimer & Co held 4,656 shares of BioMarin Pharmaceuticals worth $279K as of Q3 2026.
- Oppenheimer & Co left its BioMarin Pharmaceuticals share count unchanged in Q3 2026.
- BioMarin Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1465 holding.
- Oppenheimer & Co first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 14 quarters since.
- Oppenheimer & Co's BioMarin Pharmaceuticals position peaked at $1.62M in Q2 2015.
- 567 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.
Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.